MAPROTILINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Maprotiline Hydrochloride, and what generic alternatives are available?
Maprotiline Hydrochloride is a drug marketed by Am Therap, Heritage Pharma, Rising, and Watson Labs. and is included in ten NDAs.
The generic ingredient in MAPROTILINE HYDROCHLORIDE is maprotiline hydrochloride. There are three drug master file entries for this compound. Additional details are available on the maprotiline hydrochloride profile page.
Summary for MAPROTILINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 10 |
Raw Ingredient (Bulk) Api Vendors: | 110 |
Clinical Trials: | 3 |
Patent Applications: | 884 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MAPROTILINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MAPROTILINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Rochester | Phase 1 |
Hannover Medical School | Phase 3 |
US Department of Veterans Affairs | Phase 2 |